Assuntos
Aconitina/análogos & derivados , Aconitum/análogos & derivados , Arritmias Cardíacas/tratamento farmacológico , Aconitina/administração & dosagem , Aconitina/farmacocinética , Aconitina/uso terapêutico , Arritmias Cardíacas/metabolismo , Disponibilidade Biológica , Ensaios Clínicos como Assunto , Humanos , ComprimidosRESUMO
Pharmacokinetics of allapinin tablets, used as a single dose, alone or in combination with other antiarrhythmic drugs (cordarone, mexitil, ritmilen) were assessed in 11 patients with frequent extrasystoles. Allapinin pharmacokinetic pattern was basically similar in patients in whom it was very effective and those in whom it had no effect. Combined use of the above-mentioned antiarrhythmic drugs and allapinin did not affect the latter's pharmacokinetic parameters. Allapinin pharmacokinetics can be described using a one-part model.
Assuntos
Aconitina/análogos & derivados , Aconitum/análogos & derivados , Complexos Cardíacos Prematuros/tratamento farmacológico , Taquicardia Supraventricular/tratamento farmacológico , Aconitina/administração & dosagem , Aconitina/farmacocinética , Complexos Cardíacos Prematuros/metabolismo , Relação Dose-Resposta a Droga , Humanos , Comprimidos , Taquicardia Supraventricular/metabolismo , Fatores de TempoRESUMO
Pharmacokinetics and pharmacodynamics of a new antiarrhythmic drug allapinin was studied in patients with frequent ventricular and supraventricular extrasystoles. The technique of determining allapinin by high performance liquid chromatography is described. Intravenous administration of the drug in a dose of 20 mg was shown to be effective in 50% of patients.
Assuntos
Aconitina/análogos & derivados , Aconitum/análogos & derivados , Aconitina/farmacocinética , Aconitina/farmacologia , Aconitina/uso terapêutico , Complexos Cardíacos Prematuros/sangue , Complexos Cardíacos Prematuros/tratamento farmacológico , Complexos Cardíacos Prematuros/fisiopatologia , Cromatografia Líquida de Alta Pressão/instrumentação , Cromatografia Líquida de Alta Pressão/métodos , Doença das Coronárias/sangue , Doença das Coronárias/tratamento farmacológico , Doença das Coronárias/fisiopatologia , Avaliação de Medicamentos , Eletrocardiografia , Frequência Cardíaca/efeitos dos fármacos , Humanos , Fatores de TempoRESUMO
Ethynyl-estradiol was shown to decrease the rate of biosynthesis of saturated, mono-, di-, tri- and tetraenic fatty acids in liver tissue and to increase the esterification of the newly synthesized fatty acids into triglycerides and phospholipids. The most distinct activation of esterification was found, if newly synthesized saturated fatty acids changed to triglycerides and tetraenic acids--into phospholipids. Ethynyl-estradiol stimulated also in liver tissue the esterification of exogenous saturated and unsaturated fatty acids into triglycerides and phospholipids, while relative esterification of unsaturated fatty acids into phospholipids tended to increase. The data obtained suggest that stimulation of endo- and exogenous fatty acids esterification into triglycerides and phospholipids of liver tissue may be important in pathogenesis of estrogen-induced hypertriglyceridemia.